Moreover, treatment of the CEP290 c.2991+1655A>G variant with the RNA antisense oligonucleotide (AON) sepofarsen (QR-110) restored CEP290 function in preclinical models [8], improved visual acuity in phase Ib/II clinical trials [9,10,11], and improved cone sensitivity in individuals with congenital blindness [12]. This evidence concerns the gene CEP290 and congenital stationary night blindness.